JP2015500840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500840A5 JP2015500840A5 JP2014547627A JP2014547627A JP2015500840A5 JP 2015500840 A5 JP2015500840 A5 JP 2015500840A5 JP 2014547627 A JP2014547627 A JP 2014547627A JP 2014547627 A JP2014547627 A JP 2014547627A JP 2015500840 A5 JP2015500840 A5 JP 2015500840A5
- Authority
- JP
- Japan
- Prior art keywords
- apolipoprotein
- formulation
- fixed dosage
- dosage
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000007592 Apolipoproteins Human genes 0.000 claims 48
- 108010071619 Apolipoproteins Proteins 0.000 claims 48
- 239000000203 mixture Substances 0.000 claims 37
- 238000009472 formulation Methods 0.000 claims 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 150000002632 lipids Chemical class 0.000 claims 10
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 6
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 4
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 4
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010020961 Hypocholesterolaemia Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000005022 packaging material Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2011905368 | 2011-12-21 | ||
| AU2011905368A AU2011905368A0 (en) | 2011-12-21 | Dosing regime for apolipoprotein formulations | |
| PCT/AU2012/001345 WO2013090978A1 (en) | 2011-12-21 | 2012-11-02 | Dosage regime for apolipoprotein formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017045676A Division JP2017128586A (ja) | 2011-12-21 | 2017-03-10 | アポリポタンパク質製剤のための投与計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500840A JP2015500840A (ja) | 2015-01-08 |
| JP2015500840A5 true JP2015500840A5 (enExample) | 2015-12-10 |
| JP6144276B2 JP6144276B2 (ja) | 2017-06-07 |
Family
ID=48667485
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547627A Active JP6144276B2 (ja) | 2011-12-21 | 2012-11-02 | アポリポタンパク質製剤のための投与計画 |
| JP2017045676A Pending JP2017128586A (ja) | 2011-12-21 | 2017-03-10 | アポリポタンパク質製剤のための投与計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017045676A Pending JP2017128586A (ja) | 2011-12-21 | 2017-03-10 | アポリポタンパク質製剤のための投与計画 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20140378376A1 (enExample) |
| EP (1) | EP2793913B1 (enExample) |
| JP (2) | JP6144276B2 (enExample) |
| KR (3) | KR20140107536A (enExample) |
| CN (2) | CN104010646A (enExample) |
| AU (1) | AU2012310259C1 (enExample) |
| BR (1) | BR112014014403A8 (enExample) |
| CA (1) | CA2857968A1 (enExample) |
| DK (1) | DK2793913T3 (enExample) |
| ES (1) | ES2955110T3 (enExample) |
| IL (1) | IL233236A0 (enExample) |
| MX (1) | MX377093B (enExample) |
| PL (1) | PL2793913T3 (enExample) |
| RU (1) | RU2014129505A (enExample) |
| SG (1) | SG11201402556RA (enExample) |
| WO (1) | WO2013090978A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9645037B2 (en) | 2011-09-28 | 2017-05-09 | Hunter Engineering Company | Method and apparatus for wheel assembly lateral force measurement |
| CA2857968A1 (en) * | 2011-12-21 | 2013-06-27 | Csl Limited | Dosage regime for apolipoprotein formulations |
| WO2018085890A1 (en) | 2016-11-10 | 2018-05-17 | Csl Limited | Reconstituted high density lipoprotein treatment of myocardial infarction |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61152632A (ja) * | 1984-12-26 | 1986-07-11 | Dai Ichi Seiyaku Co Ltd | 抗動脈硬化剤 |
| US5652339A (en) | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| WO2002038609A2 (en) * | 2000-11-10 | 2002-05-16 | Proteopharma Aps | Apolipoprotein conjugates |
| CA2460787A1 (en) * | 2001-09-28 | 2003-04-03 | Esperion Therapeutics, Inc. | Prevention and treatment of restenosis by local administration of drug |
| BR0310099A (pt) * | 2002-05-17 | 2007-03-20 | Esperion Therapeutics Inc | método para tratar dislipidemia ou uma doença associada com a dislipidemia |
| WO2004010939A2 (en) * | 2002-07-30 | 2004-02-05 | Esperion Therapeutics, Inc. | Methods of using non-human animal apoliprotein a-i protein |
| PE20050438A1 (es) * | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| CN1870894B (zh) * | 2003-10-20 | 2011-08-10 | 埃斯普里昂治疗公司 | 用于治疗和预防急性冠状动脉综合征的药物制剂、方法和给药方案 |
| WO2007023476A2 (en) * | 2005-08-26 | 2007-03-01 | Cerenis Therapeutics Holding Sa | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
| US20090297577A1 (en) * | 2008-06-02 | 2009-12-03 | Medtronic Vascular, Inc. | Local Delivery of Apolipoproteins and Their Derivatives |
| CA2857968A1 (en) * | 2011-12-21 | 2013-06-27 | Csl Limited | Dosage regime for apolipoprotein formulations |
-
2012
- 2012-11-02 CA CA2857968A patent/CA2857968A1/en not_active Abandoned
- 2012-11-02 CN CN201280063210.4A patent/CN104010646A/zh active Pending
- 2012-11-02 KR KR1020147020291A patent/KR20140107536A/ko not_active Ceased
- 2012-11-02 KR KR1020197019295A patent/KR20190084334A/ko not_active Ceased
- 2012-11-02 JP JP2014547627A patent/JP6144276B2/ja active Active
- 2012-11-02 EP EP12859136.9A patent/EP2793913B1/en active Active
- 2012-11-02 WO PCT/AU2012/001345 patent/WO2013090978A1/en not_active Ceased
- 2012-11-02 CN CN202110675512.8A patent/CN113398245A/zh active Pending
- 2012-11-02 RU RU2014129505A patent/RU2014129505A/ru unknown
- 2012-11-02 DK DK12859136.9T patent/DK2793913T3/da active
- 2012-11-02 KR KR1020207009276A patent/KR102766038B1/ko active Active
- 2012-11-02 PL PL12859136.9T patent/PL2793913T3/pl unknown
- 2012-11-02 US US14/364,764 patent/US20140378376A1/en not_active Abandoned
- 2012-11-02 SG SG11201402556RA patent/SG11201402556RA/en unknown
- 2012-11-02 AU AU2012310259A patent/AU2012310259C1/en active Active
- 2012-11-02 MX MX2014006589A patent/MX377093B/es active IP Right Grant
- 2012-11-02 BR BR112014014403A patent/BR112014014403A8/pt not_active Application Discontinuation
- 2012-11-02 ES ES12859136T patent/ES2955110T3/es active Active
-
2014
- 2014-06-18 IL IL233236A patent/IL233236A0/en active IP Right Grant
-
2016
- 2016-02-26 US US15/054,358 patent/US20160175392A1/en not_active Abandoned
-
2017
- 2017-03-10 JP JP2017045676A patent/JP2017128586A/ja active Pending
-
2023
- 2023-08-14 US US18/449,039 patent/US20240216467A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ruge et al. | Pulmonary drug delivery: from generating aerosols to overcoming biological barriers—therapeutic possibilities and technological challenges | |
| Wauthoz et al. | Phospholipids in pulmonary drug delivery | |
| Chan et al. | Advances in device and formulation technologies for pulmonary drug delivery | |
| JP2015515992A5 (enExample) | ||
| JP2020172514A5 (enExample) | ||
| Andrade | Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression | |
| Young et al. | Overcoming dose limitations using the Orbital® multi-breath dry powder inhaler | |
| JP2017534604A5 (enExample) | ||
| CN103002877A (zh) | 作为缓解疾病的抗风湿性药（dmard）和抗癌药剂的甲氨蝶呤的持续释放制剂 | |
| JP2018519818A5 (enExample) | ||
| Mula | New non-intravenous routes for benzodiazepines in epilepsy: a clinician perspective | |
| RU2017115990A (ru) | Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии | |
| RU2005115956A (ru) | Способ лечения инсулинорезистентности, диабета взрослых и метаболического синдрома х | |
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| JP6340372B2 (ja) | 再構成されたｈｄｌ製剤 | |
| JP2018531605A5 (enExample) | ||
| IL250302B (en) | Apoe mimetic peptides and higher potency to clear plasma cholesterol | |
| Chopra et al. | Liposomes as nanocarriers for anti-HIV therapy | |
| JP2018507901A5 (ja) | Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法 | |
| US20240216467A1 (en) | Dosage regime for apolipoprotein formulations | |
| JP2015500840A5 (enExample) | ||
| Kumar | Co-aerosolized pulmonary surfactant and ambroxol for COVID-19 ARDS intervention: what are we waiting for? | |
| Lapidot et al. | A novel faster-acting, dry powder-based, naloxone intranasal formulation for opioid overdose | |
| Paccaly et al. | Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects | |
| CN110121358A (zh) | 一种预防和治疗肺纤维化的方法 |